Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company, announced that it has commenced a Post Marketing Surveillance (PMS) study on FabiFlu to closely monitor the efficacy and safety of the drug in 1000 patients that are prescribed with the oral antiviral, as part of an open label, multicenter, single arm study. Further, Glenmark has announced…